Abstract:Objective To analyze the clinical features,diagnosis and management of double seropositive myasthenia gravis (MG),which means both antibodies to acetylcholine receptors (AChR-Ab) and muscle specific tyrosine kinase (MuSK-Ab) are positive.The data of our three patients and cases which have been reported were analyzed together for making a full understanding of this rare condition.Methods A search was conducted for papers published on Medline and Wanfang database in the recent 20 years to study cases on double seropositive MG in terms of clinical features,electrophysiology and laboratory tests,management and prognosis.Data of our three patients and previous reported cases were analyzed together.Results Eight papers reporting seven patients met the inclusion criteria.In total ten patients were analyzed,including four males and six females,mean age (45.5±24.1) yeavs.The onset symptoms varied form,ptosis,diplopia to dyspnea.The involved muscles included extra ocular muscles (9/10),bulbar muscles (9/10),proximal limbs (8/10),neck extensor (7/10) and respiratory muscles (6/10).The incidence of myasthenic crisis was as high as 50％.9 patients underwent electromyography (EMG),the positive rate of repetitive nerve stimulation (RNS) of was 88.9％,the positive rate of single fiber EMG (SFEMG) was 100％.The double positive antibodies could not only be identified in the deterioration phase of anti-AChR positive MG,but also identified the first examination.The patients were often responsive to the treatments of pyridostigmine and immunosupressive drugs,and patients with crisis (4/4) can be markedly improved by plasma exchange (PE),Rituximab was beneficial for severe symptoms such as dyspnea (2/2),cyclosporine was partial beneficial in 1 of 2 and not responsive in the rest,azathioprine was not responsive to all.The double positive antibodies might change during remission.Conclusions The double seropositive MG can be involved at any age,with a female dominance,and generalized muscle involvement,and are more likely to be in severe conditions.The benefit of immunosuppressive drug therapy varied.PE is beneficial for crisis treatment.The results of antibodies identification can change with the clinical exacerbation and remission.

Clinical significance of serum antibodies in different types of myasthenia gravis

Detection and Clinical Significance of Serum Autoantibodies in Patients with Myasthenia Gravis

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

The Clinical Significance of Serum Anti-Titin Antibodies and Anti-Acetylcholine Receptor Antibodies in Patients with Myasthenia Gravis

The Significance of Serum Anti-Titin Antibodies and Anti-Acetylcholine Receptor Antibodies in Patients with Myasthenia Gravis

Detection of Four Serum Antibodies in Myasthenia Gravis Patients and Its Clinical Values

Serum Titin antibody and Ryanodine receptor antibody in patients with myasthenia gravis

Detection of Multiple Antibodies in Myasthenia Gravis and Its Clinical Significance

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

[Distribution Characteristics and Correlation Analysis of Antibody Detection Value in Myasthenia Gravis].

Titin antibody in myasthenia gravis and its clinical significance

Cortactin Antibody in Myasthenia Gravis and Its Clinical Significance

Serum ryanodine receptor antibody on the assessment of clinical symptoms in patients with myasthenia gravis

The Clinical Significance of Serum Anti-Titin Antibody Test in Patients with Myasthenia Gravis

Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls

Detection of Ryanodine receptor antibody in sera of myasthenia gravis patients and its clinical significance

Advances of Serum Antibodies in Myasthenia Gravis

The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis.

Plasma Levels and Clinical Significance of Complement Activation Products in Generalized Myasthenia Gravis Patients with Acetylcholine Receptor Antibodies

A radioimmunoassay for the quantitative evaluation of acetylcholine receptor antibodies and its clinical correlations in myasthenia gravis

Three AChR-Ab and MuSK-Ab double-seropositive myasthenia gravis patients and review of literature